Monopar Therapeutics MNPR shares are trading higher on Tuesday, after the company announced it joined forces with NorthStar to develop a radio-immuno-therapeutics to target severe coronavirus.
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. Its pipeline products comprise of Validive, Camsirubicin, and MNPR-101.
Monopar Therapeutics shares were trading up 11.64% at $9.21 at the time of publication on Tuesday. The stock has a 52-week high of $48 and a 52-week low of $4.94.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
